RPRX insider trading
NasdaqGS HealthcareRoyalty Pharma plc: insider trade history from SEC Form 4 filings.
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Company website: www.royaltypharma.com
RPRX insider activity at a glance
FilingIQ tracks 520 insider transactions for RPRX in filings since Jan 7, 2016. The most recent transaction is dated Oct 5, 2026.
Across the full history, 27 open-market purchases
and 263 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on RPRX insider trades is 60.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest RPRX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for RPRX?
- FilingIQ tracks 520 Form 4 insider transactions for RPRX (Royalty Pharma plc), covering filings from Jan 7, 2016 onwards. 13 of those are dated within the last 90 days.
- Are RPRX insiders net buyers or net sellers?
- Across the full Form 4 history for RPRX, 27 transactions (5%) were open-market purchases and 263 (51%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does RPRX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is RPRX in?
- Royalty Pharma plc (RPRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.30B.
Methodology & sources
Every RPRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.